Work

Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients

Year: 2013

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-013-9956-5

Authors: Douglas A. Rubinson, Howard S. Hochster, David P. Ryan, Brian M. Wolpin, Nadine Jackson McCleary, Thomas A. Abrams, Jennifer A. Chan, Syma Iqbal, Heinz J. Lenz, Dean Lim, Jeffrey Rose, Tanios Bekaii-Saab, Helen X. Chen, Charles S. Fuchs, Kimmie Ng

Institutions: Dana-Farber Cancer Institute, Yale Cancer Center, Massachusetts General Hospital, USC Norris Comprehensive Cancer Center, City Of Hope National Medical Center, The Ohio State University, National Institutes of Health, National Cancer Institute

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Bristol-Myers Squibb, National Institutes of Health, Genentech, National Cancer Institute

Awards: G1423636853, G1460768082, Cohort Study of Biochemical and Genetic Risk Factors for Pancreatic Cancer, Cancer Center Support Grant

OpenAlex ID: W2020603148

FWCI: 3.319

Cites: 35

Cited by: 56

Related to: 10